Covista (CVSA) CEO Beard, Stephen W. Sells $610K of Stock

Stephen Beard, the Chairman and CEO of Covista Inc. (NYSE: CVSA), sold 4,667 shares on October 9, 2026, for a total value of about $610,298.92. The shares were sold at an average price of $130.77 each. Beard's sale was planned, indicating it was likely part of a pre-arranged trading strategy.

Other Institutional Activity in Covista Inc.

Several other institutional investors have also been active with Covista's stock. Blackrock Inc. increased its stake by 251,007 shares, holding a total of 5,480,326 shares valued at approximately $694.6 million. FMR, LLC added 564,015 shares, bringing its total to 3,218,203 shares worth about $407.9 million. Meanwhile, Vanguard Portfolio Management LLC slightly reduced its holdings by 34,629 shares, ending with 2,386,958 shares valued at around $302.5 million.

Covista Inc. Stock Holds Steady

Covista Inc.'s stock is currently trading around $127.28, which is below its 50-day moving average of $128.35 but above its 200-day average of $118.67. The shares are also 18.5% below their 52-week high of $156.26, yet they remain 46.3% above the 52-week low of $86.97. This positioning suggests the stock has seen some volatility over the past year.

Recent Earnings

Covista reported trailing twelve-month revenue of approximately $1.95 billion and earnings per share (EPS) of $7.49. The company has experienced a year-over-year revenue growth of 9.7%. Its next earnings report is scheduled for October 29, 2026.

Insider Buying and Selling at Covista Inc.

In addition to Beard's recent sale, other insiders have also sold shares recently. Douglas G. Beck, the General Counsel, sold 4,526 shares on August 7, 2026, at $135.81 each for a total of $614,676. Chief Financial Officer Robert John Phelan sold 2,186 shares on the same day at $135.15, totaling $295,438. CEO Stephen Beard himself sold 3,545 shares on August 11, 2026, at $130.34 each, amounting to $462,073. These recent sales indicate a trend among the company's executives to liquidate some of their holdings.

Analysts Set New Price Targets

On September 3, 2026, Truist Securities downgraded its rating on Covista to 'Hold' with a price target of $140. BMO Capital maintained its 'Outperform' rating with a slightly reduced target of $145 on October 5, 2026. The consensus among analysts is a 'buy' recommendation with a mean price target of $158.75, reflecting optimism about Covista's future performance.

About Covista Inc.

Covista Inc. provides healthcare education services across the United States and several Caribbean nations. The company operates three main segments: Chamberlain, Walden, and Medical and Veterinary. Its focus on education in healthcare positions it well within the growing demand for skilled professionals in the sector.

Bottom Line

Investors should watch for Covista's next earnings report on October 29, 2026, to gauge its financial health following these insider sales. Additionally, the recent analyst ratings indicate mixed sentiments, which could influence the stock's performance in the near term.